COMMUNIQUÉS West-GlobeNewswire
-
First cases using Smith+Nephew’s new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
18/09/2024 - 16:00 -
Kaida BioPharma Launches Social Media Channels
18/09/2024 - 16:00 -
Corza Medical figure dans la liste MedTech Big 100 de 2024
18/09/2024 - 16:06 -
Tilray Medical lance la marque de cannabis Redecan en Australie
18/09/2024 - 16:11 -
Starton Therapeutics Announces Successful Feasibility Demonstration of STAR-LLD Using BD Evolve™ On-Body Injector
18/09/2024 - 16:46 -
Plant Advanced Technologies PAT : Bilan 1er semestre 2024 du contrat de liquidité
18/09/2024 - 18:00 -
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
18/09/2024 - 10:45 -
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
18/09/2024 - 11:00 -
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
18/09/2024 - 12:00 -
KFSHRC Celebrates Landmark Contributions at 2024 NYC C3 Summit Davos of Healthcare
18/09/2024 - 12:00 -
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
18/09/2024 - 12:15 -
Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia
18/09/2024 - 13:00 -
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
18/09/2024 - 13:00 -
Tilray Medical Launches Redecan Cannabis Brand in Australia
18/09/2024 - 13:00 -
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia
18/09/2024 - 13:00 -
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
18/09/2024 - 13:00 -
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
18/09/2024 - 13:00 -
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
18/09/2024 - 13:00 -
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
18/09/2024 - 13:15
Pages